M1041 Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)? : A Community-Based US Survey Study

Chey, William D.; Mody, Reema; Kothari, Smita; Wu, Eric; Chen, Lei; Persson, Bjorn; Beaulieu, Nancy; Lu, Mei

doi:10.1016/s0016-5085(08)61517-6

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…33 Of those patients on PPI twice daily, almost 40% stated that they doubled the dose due to inadequate control of nighttime GERD-related symptoms. 34 Several studies have also shown that the response rate of PPI once daily for nighttime heartburn is significantly lower (up to 53%) than the response rate for daytime heartburn (up to 66%). 35,36 In summary, nighttime heartburn has the most important impact on the quality of life for GERD patients.…”

Section: Nighttime Heartburnmentioning

confidence: 99%

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Dickman

Maradey–Romero

Gingold‐Belfer

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is a highly prevalent gastrointestinal disorder. Proton pump inhibitors have profoundly revolutionized the treatment of GERD. However, several areas of unmet need persist despite marked improvements in the therapeutic management of GERD. These include the advanced grades of erosive esophagitis, nonerosive reflux disease, maintenance treatment of erosive esophagitis, refractory GERD, postprandial heartburn, atypical and extraesophageal manifestations of GERD, Barrett's esophagus, chronic protein pump inhibitor treatment, and post-bariatric surgery GERD. Consequently, any future development of novel therapeutic modalities for GERD (medical, endoscopic, or surgical), would likely focus on the aforementioned areas of unmet need.

show abstract

Section: Nighttime Heartburnmentioning

confidence: 99%

Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Dickman

Maradey–Romero

Gingold‐Belfer

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…It has been shown that healing in acid‐related disorders is directly related to the degree and duration of acid suppression and the length of treatment 1–4 . However, a significant number of patients with acid‐related disorders do not adequately respond to once or even twice daily PPI therapy 5, 6 . A suboptimal symptomatic response to PPI therapy commonly leads the physician to double the PPI dose 6 …”

Section: Introductionmentioning

confidence: 99%

“…However, a significant number of patients with acid‐related disorders do not adequately respond to once or even twice daily PPI therapy 5, 6 . A suboptimal symptomatic response to PPI therapy commonly leads the physician to double the PPI dose 6 …”

Section: Introductionmentioning

confidence: 99%

The pharmacodynamics and pharmacokinetics of S‐tenatoprazole‐Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects

Hunt

Armstrong

Yaghoobi

et al. 2010

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Indeed, as many as 25% of GERD patients are not satisfied with their therapy. 2 These needs can be divided into 2 categories: rapid onset of symptom relief and sustained activity (particularly through the night). The lack of a rapid onset of activity of PPIs is largely attributable to the fact that they are acid-labile, so PPIs have to be administered in formulations that protect the drug until it enters the duodenum.…”

mentioning

confidence: 99%